万维提示：
1、该刊只有国际刊号。
2、投稿方式：在线投稿。
3、官网网址：
https://journals.lww.com/dm/pages/default.aspx
（主办单位微信公众号信息）
4、投稿系统：
https://www.editorialmanager.com/dm/default2.aspx
5、官网邮箱：editor@digitmedicine.com
6、出刊日期：季刊，逢季末月出版。
7、官网信息：作者发表无需承担任何费用
8、主办单位微信公众号：大医二院学科建设与科研管理部
2026年4月23日星期四
《Digital Medicine》期刊2026年第一期正式上线！
【主办单位微信公众号信息】
大医二院学科建设与科研管理部 2026年4月1日
近日，由大连医科大学附属第二医院主办、国际数字医学会提供学术支持的 《Digital Medicine》期刊2026年第一期正式上线！
期刊简介
《Digital Medicine》(ISSN 2542-629X)是由大连医科大学附属第二医院主办的一本经过严格同行评议的在线连续出版期刊，以全英文形式出版，季刊发行。本刊实行开放获取（Open Access）模式，所有内容均可免费阅读、下载和传播。期刊面向全球发行，作者发表无需承担任何费用，包括稿件提交费、处理费、出版费及图片彩色印刷费均予免除。本刊实行严格的匿名同行评审制度，确保学术评价的公正性与学术诚信，致力于构建一个充满活力、兼具包容性的学术共同体，倡导思想多元，鼓励创新探索。
征稿范围
《Digital Medicine》 收录范围涵盖：医学影像研究、数字与信息技术、人类与数字解剖相关研究、计算机辅助设计/制造/分析技术在临床中的应用研究、人工智能应用、数字医院建设与管理、生物工程、放射诊断与放射治疗、区域医疗协同与信息资源共建共享数据库建设、远程医疗会诊与教育，以及其他相关分支学科。期刊优先发表具有临床价值及临床转化意义的文章。
欢迎投稿
目前期刊2026年第一期已正式上线，各项投稿通道持续开放。欢迎临床医生和科研工作者踊跃投稿！
投稿方式：https://www.editorialmanager.com/dm/default2.aspx本刊官网：https://journals.lww.com/dm/pages/default.aspx编辑部邮箱：editor@digitmedicine.com
Instructions for Authors
【官网信息】
The Editorial Office is pleased to answer any questions you may have about preparing your manuscript in accordance with our guidelines.
Email: editor@digitmedicine.com
AIMS AND SCOPE
Digital Medicine, a publication of International Society of Digital Medicine, and academically supported by Second Hospital of Dalian Medical University, is a peer-reviewed online continuous publishing journal The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal does not charge for submission, processing or publication of manuscripts and even for color reproduction of photographs.
The scope of Digital Medicine covers the medical imaging research, digital and information technology, human and digital anatomy related research, computer-aided design/manufacturing/analysis technology in clinical application research, artificial intelligence application, digital hospital construction and management, bioengineering, radiological diagnosis and radiotherapy, regional medical collaboration and information resource sharing database construction, telemedicine consultation and education and other sub-disciplines. Articles with clinical interest and implications will be given preference.
ONLINE SUBMISSION
First-time Users
Please click the Register button at https://www.editorialmanager.com/dm/default2.aspx. Upon successful registration, you will be sent an email providing your username and password. Save this information for future reference.
Note: If you have received an email from us with an assigned username and password, or if you are a repeat user, do not register again. Once you have an assigned username and password, you do not have to re-register.
Authors
Please click the Login button from the menu at the top of the page and login to the system as an author. Submit your manuscript according to the author instructions. You will be able to track the process of your manuscript through the system.
JOURNAL POLICIES
Duplicate Publication
Manuscripts are reviewed for possible publication with the understanding that they are being submitted only to the Digital Medicine and have not been published, simultaneously submitted, or already accepted for publication elsewhere. The Editorial team may subject any manuscript submitted for consideration of publication in the Digital Medicine to plagiarism-detection software.
This does not preclude consideration of a manuscript that has been rejected by another journal or a complete report that follows publication of preliminary findings elsewhere, usually in the form of an abstract. Copies of any possibly duplicate published material should be submitted with the manuscript under consideration, with a statement in the cover letter as to why the manuscript currently being submitted is not a duplicate publication.
Disclosure of Conflicts
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript.
All relevant conflicts of interest and financial support and sponsorship should be included on the title page of the manuscript with the heading "Conflicts of interest" and "Financial support and sponsorship ".
For example: "Conflicts of interest: *** is an Editor-in-Chief/Associate Editor/Editorial Board Member of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of this editor and his research groups. /A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker's bureau for Organization X - the CME organizers for Company A./There are no conflicts of interest."
"Financial support and sponsorship": This study was supported by grants from xxx."
A financial disclosure section is part of the submission process and must be completed by each author at first revision. This information is for review by the Editors but will be published if relevant to the content of the accepted manuscript.
The primary purpose of the disclosure section is to determine whether authors have received any commercial financial support that could create a conflict of interest. In addition to monetary interests, a potential for conflict of interest can exist whether or not an individual believes that a relationship (such as dual commitments, competing interests, or competing loyalties) affects his or her scientific judgment. Please review ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals at the following link:
http://www.icmje.org/conflicts-of-interest.
Studies in Humans and Animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.
Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
Authors describing studies involving animals must have consulted the ‘Animal Research: Reporting In Vivo Experiments’ (ARRIVE) 2.0 guidelines, developed by the NC3Rs to improve standards of reporting, ensuring that the data from animal experiments can be fully scrutinized and utilized. Articles reporting in vivo experiments must adhere to the ARRIVE Essential 10 checklist as a minimum, and we encourage authors to use the full ARRIVE 2.0 checklist. The relevant information outlined in these guidelines should be included in the appropriate section of the article. All animal experiments should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.
Ethics
When reporting studies on human subjects, author should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). For prospective studies involving human participants, authors are expected to mention about approval of regional/national/institutional or independent ethics committee or review board, obtaining informed consent from adult research participants and obtaining assent for children aged over 7 years participating in the trial. The age beyond which assent would be required could vary as per regional and/or national guidelines. Ensure confidentiality of subjects by desisting from mentioning participants' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution's or a national research council's guide for, or any national law on the care and use of laboratory animals was followed.
Evidence for approval by a local ethics committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible, and the details of anesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the CPCSEA and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving experimental animals and human beings, respectively. The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the "Methods" section.
We reserve the right to decline publication of a paper even after it has been accepted if it becomes apparent that there are serious problems with the scientific content or violations of our publishing policies.
Protection of Patients' Rights to Privacy
Identifying information should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian, wherever applicable) gives written informed consent for publication. Authors should remove patients' names from figures unless they have obtained written informed consent from the patients. The journal abides by ICMJE guidelines: (1) Authors, not the journals nor the publisher, need to have the patient consent form before the publication related to patient privacy and have the form properly archived by the author. (2) If the publication includes some facial images that make the patients identifiable, a statement about the patient's consent needs to be present in the manuscript.
Data Availability Statement
Digital Medicine requires authors to include in any articles that report results derived from research data to include a Data Availability Statement. The provision of a Data Availability Statement will be verified as a condition of publication. Data Availability Statements should include information on where data supporting the results reported in the article can be found including, where applicable, hyperlinks to publicly archived datasets analyzed or generated during the study. Where research data are not publicly available, this must be stated in the manuscript along with any conditions for accessing the data. Data Availability Statements must take one of the following forms (or a combination of more than one if required for multiple types of research data):
The datasets generated during and/or analyzed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]
The datasets generated during and/or analyzed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name].
AUTHORSHIP
Digital Medicine expects that each person listed as an author has participated sufficiently in the intellectual content, the analysis of data, and/or the writing of the manuscript to take public responsibility for it. Each author must have reviewed the manuscript, believes it represents valid work, and approves it for submission.
Moreover, should the Editorial team request the data upon which the manuscript is based, the authors shall provide the data. Each author’s specific contributions to the work should be indicated; this information will be published as a footnote to the paper. For example, the areas of participation might include:
Participated in research design
Participated in the writing of the paper
Participated in the performance of the research
Contributed new reagents or analytic tools
Participated in data analysis
An author may list more than one contribution, and more than one author may have contributed to the same aspect of the work. Any change in authorship/contributions after submission must be approved in writing by all authors and submitted to the Editorial Office for final consideration.
AI Announcement
Authors are fully responsible for the content of their manuscript, even those parts produced by GenAI. Authors who have used GenAI in their research and the writing of manuscripts should provide an open, transparent, and detailed description of the use of GenAI (including the name and version of the GenAI tool, when it was used, how it was used, and the process of using it, and, if necessary, annotations for AI-assisted contents dealing with facts and opinions), and review of GenAI, following the body of the text, before the references, or in the method section (e.g., the authors have reviewed and edited the GenAI-produced content, and take full responsibility for the authenticity and accuracy of the content of this paper). It is recommended that authors submit and archive the GenAI-assisted sections (text, figures, programs, etc.) as supplementary material so that reviewers and editors can judge the accuracy, integrity,and originality of the paper.
Since GenAI cannot meet the requirements for authorship as they cannot take responsibility for the submitted work, GenAI -related products and developing teams cannot be listed as the author of a paper.
GenAI cannot be used to write an entire paper or a significant portion of a paper (e.g., method, result and analysis, etc.). All content that falls under the category of scientific contribution or intellectual labor should be finished by the author. If the main content of the paper is completed using GenAI, the editorial office will handle it as academic misconduct.
Plagiarism
As defined by the World Association of Medical Editors (http://www.wame.org/resources/publication-ethics-policies-for-medical-journals), plagiarism is the use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source. The intent and effect of plagiarism is to mislead the reader as to the contributions of the plagiarizer. This applies whether the ideas or words are taken from abstracts, research grant applications, Institutional Review Board applications, or unpublished or published manuscripts in any publication format (print or electronic).
Digital Medicine is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. iThenticate checks submissions against millions of published research papers, and billions of web content. Authors, researchers and freelancers can also use iThenticate to screen their work before submission by visiting http://www.ithenticate.com.
All allegations of plagiarism are investigated in accordance with the Committee on Publication Ethics (COPE) guidelines detailed at https://publicationethics.org/files/u7140/plagiarism%20A.pdf. When plagiarism is detected at any time before or after publication, the journal editorial office will take appropriate action as directed by the standards set forth by COPE. If plagiarism is found, the author, the author's institution and funding agencies, and the original publication will be notified. A statement noting the plagiarism, providing a reference to the plagiarized material, and linking to the original paper may follow. Depending on the extent of the plagiarism, the paper may also be formally retracted. For additional information, please visit http://www.publicationethics.org.
ENGLISH LANGUAGE ASSISTANCE
Appropriate use of the English language is a requirement for publication in the Digital Medicine. Authors having difficulty in writing in English who submit manuscripts to international journals often receive negative comments from referees or editors about the English-language usage in their manuscripts, and these challenges can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors consider using Wolters Kluwer Author Services**.
Wolters Kluwer Author Services
Wolters Kluwer, in partnership with Editage, offers a unique range of editorial services to help you prepare a submission-ready manuscript:
Premium Editing: Intensive language and structural editing of academic papers to increase chances of journal acceptance.
Advanced Editing: A complete language, grammar, and terminology check to give you a publication-ready manuscript.
Translation with Editing: Write your paper in your native language and Wolters Kluwer Author Services will translate it into English, as well as edit it to ensure that it meets international publication standards.
Plagiarism Check: Helps ensure that your manuscript contains no instances of unintentional plagiarism.
Artwork Preparation: Save precious time and effort by ensuring that your artwork is viewed favorably by the journal without you having to incur the additional cost of purchasing special graphics software.
For more information regarding Wolters Kluwer Author Services, please visit http://wkauthorservices.editage.com.
**Note that the use of such a service is at the author's own expense and risk, and does not guarantee that the article will be accepted.
PEER REVIEW
Digital Medicine operates a double-blind external peer review process. Digital Medicine invites worldwide experts in the relevant field to make a double-blind peer review of manuscripts submitted by authors. Review comments are fully considered to ensure the academic value of the journal. The primary task of reviewers is to evaluate the validity of the approach, the significance and originality of the finding, its interest and timeliness to the scientific community, and the clarity of the writing. A qualified peer reviewer should send his/her feedback (even decline to review due to some reasons) as per the time frame of the journal. All peer reviewers must maintain a strict and perpetual confidentiality for the content of all manuscripts under their review and for any related correspondences with BPG and/or the journal editorial team. Reviewers must not share any part of the manuscript with a third party or discuss its content with the authors of the manuscript or any other person. Reviewers must not plagiarize or cite any of the contents of a manuscript before the manuscript has been formally published. Reviewers will decline participation in the peer review process for any manuscript if a conflict of interest exists, including interests related to the manuscript's authors, personal interests, or academic or economic interests. If a conflict of interest becomes apparent during the peer review process, the reviewer must inform the Editorial Office immediately. The following reasons are adequate, alone or in combination, for rejection of a manuscript for publication: (1) The scientific content does not correspond to the journal's aims and scope; (2) The research is not reasonably designed and the data are inadequate to support proper explanations or conclusions; (3) Related work has been previously published and only a few new points have been added; (4) The article contains accumulated information that has been previously published, with only few technical improvements; (5) The article is expected to attract only a very small portion of the journal's readership audience; (6) The article has been rejected previously and resubmitted without adding any new valuable content.
Manuscripts received from Editorial Board Members will be screened by the Editor-in-Chief and sent to external peer reviewers. The Editorial Board Members, who submit manuscripts to the journal as authors or co-authors, will be excluded from publication decisions.
Manuscripts received from Editor-in-Chief will be handled by the other co-Editor-in-Chief or one of the Associate Editor of the journal and will be sent to external peer reviewers. The contributing Editor-in-Chief will be excluded from decision-making of his/her manuscript.
Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or whoever relate to products or services in which the editor has an interest. Any such submission is subject to the journal's standard procedures, with peer review handled independently of the relevant editor and their research groups.
Appeal
The authors have the right to appeal if they have a genuine cause to believe that the editorial board has wrongly rejected the paper. If the authors wish to appeal against the editorial decision, they should email the editorial office (email: editor@digitmedicine.com) explaining in detail the reason for the appeal. The appeals will be acknowledged by the editorial office and will be investigated in an unbiased manner. The processing of appeals will be done within 6-8 weeks. While under appeal, the said manuscript should not be submitted to other journals. The final decision rests with the Editor-in-Chief of the journal. Second appeals are not considered.
......
更多详见：
https://edmgr.ovid.com/dm/accounts/ifauth.htm
